

# Marc van Beurden

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8526190/publications.pdf>

Version: 2024-02-01

36  
papers

2,901  
citations

361413  
20  
h-index

345221  
36  
g-index

37  
all docs

37  
docs citations

37  
times ranked

3143  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs. <i>Cancer Treatment Reviews</i> , 2017, 52, 91-104.	7.7	398
2	Treatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod. <i>New England Journal of Medicine</i> , 2008, 358, 1465-1473.	27.0	343
3	Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. <i>Gynecologic Oncology</i> , 2005, 97, 645-651.	1.4	304
4	Quality-of-Life Effects of Prophylactic Salpingo-Oophorectomy Versus Gynecologic Screening Among Women at Increased Risk of Hereditary Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 6890-6898.	1.6	214
5	The Impact of Hormone Replacement Therapy on Menopausal Symptoms in Younger High-Risk Women After Prophylactic Salpingo-Oophorectomy. <i>Journal of Clinical Oncology</i> , 2006, 24, 3576-3582.	1.6	186
6	Efficacy of Cognitive Behavioral Therapy and Physical Exercise in Alleviating Treatment-Induced Menopausal Symptoms in Patients With Breast Cancer: Results of a Randomized, Controlled, Multicenter Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 4124-4133.	1.6	182
7	Lichen Sclerosus: Incidence and Risk of Vulvar Squamous Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1224-1230.	2.5	172
8	CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 100, 20-26.	1.4	170
9	No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. <i>British Journal of Cancer</i> , 2007, 96, 1335-1342.	6.4	134
10	Early salpingectomy (Tubectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. <i>BMC Cancer</i> , 2015, 15, 593.	2.6	88
11	Effects and moderators of psychosocial interventions on quality of life, and emotional and social function in patients with cancer: An individual patient data meta-analysis of 22 RCTs. <i>Psycho-Oncology</i> , 2018, 27, 1150-1161.	2.3	74
12	Predictors of Prophylactic Bilateral Salpingo-Oophorectomy Compared With Gynecologic Screening Use in BRCA1/2 Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2007, 25, 301-307.	1.6	73
13	Targeting Exercise Interventions to Patients With Cancer in Need: An Individual Patient Data Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1190-1200.	6.3	72
14	Squamous Vulvar Intraepithelial Neoplasia. <i>Clinical Obstetrics and Gynecology</i> , 2005, 48, 845-861.	1.1	70
15	Vulvar intraepithelial neoplasia: Incidence and long-term risk of vulvar squamous cell carcinoma. <i>International Journal of Cancer</i> , 2021, 148, 90-98.	5.1	49
16	Imiquimod-induced clearance of HPV is associated with normalization of immune cell counts in usual type vulvar intraepithelial neoplasia. <i>International Journal of Cancer</i> , 2010, 127, 2831-2840.	5.1	48
17	Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study. <i>European Journal of Cancer</i> , 2017, 84, 159-167.	2.8	40
18	Impact of risk-reducing salpingo-oophorectomy in premenopausal women. <i>Climacteric</i> , 2017, 20, 212-221.	2.4	38

#	ARTICLE	IF	CITATIONS
19	Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines. <i>Climacteric</i> , 2019, 22, 352-360.	2.4	30
20	Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in <i>&lt;i&gt;BRCA1/2&lt;/i&gt;</i> Pathogenic Variant Carriers. <i>JAMA Oncology</i> , 2021, 7, 1203.	7.1	27
21	The risk of developing squamous cell carcinoma in patients with anogenital lichen sclerosis: A systematic review. <i>Gynecologic Oncology</i> , 2020, 157, 671-677.	1.4	22
22	The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) Consensus Statements on Pre-invasive Vulvar Lesions. <i>Journal of Lower Genital Tract Disease</i> , 2022, 26, 229-244.	1.9	22
23	Molecular heterogeneity in human papillomavirusâ€dependent and â€independent vulvar carcinogenesis. <i>Cancer Medicine</i> , 2018, 7, 4542-4553.	2.8	21
24	The Paget Trial: A Multicenter, Observational Cohort Intervention Study for the Clinical Efficacy, Safety, and Immunological Response of Topical 5% Imiquimod Cream for Vulvar Paget Disease. <i>JMIR Research Protocols</i> , 2017, 6, e178.	1.0	19
25	<i>&lt;sc&gt;DNA&lt;/sc&gt;</i> methylation markers for cancer risk prediction of vulvar intraepithelial neoplasia. <i>International Journal of Cancer</i> , 2021, 148, 2481-2488.	5.1	17
26	The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) consensus statements on pre-invasive vulvar lesions. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 830-845.	2.5	17
27	The Paget Trial: topical 5% imiquimod cream for noninvasive vulvar Paget disease. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 250.e1-250.e8.	1.3	15
28	The Vulvar Cancer Risk in Differentiated Vulvar Intraepithelial Neoplasia: A Systematic Review. <i>Cancers</i> , 2021, 13, 6170.	3.7	13
29	Moderators of the effect of psychosocial interventions on fatigue in women with breast cancer and men with prostate cancer: Individual patient data metaâ€analyses. <i>Psycho-Oncology</i> , 2020, 29, 1772-1785.	2.3	11
30	Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMONy Study). <i>JMIR Research Protocols</i> , 2021, 10, e24414.	1.0	9
31	Effects and moderators of coping skills training on symptoms of depression and anxiety in patients with cancer: Aggregate data and individual patient data meta-analyses. <i>Clinical Psychology Review</i> , 2020, 80, 101882.	11.4	7
32	Changes in Sex Steroids and Relation With Menopausal Complaints in Women Undergoing Risk-reducing Salpingo-oophorectomy. <i>Journal of the Endocrine Society</i> , 2022, 6, bvac069.	0.2	5
33	Topical imiquimod as first-line treatment for vulvar intraepithelial neoplasia. <i>Lancet, The</i> , 2022, 399, 1755-1757.	13.7	5
34	Does anti-MÃ¼llerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study. <i>Climacteric</i> , 2018, 21, 574-580.	2.4	3
35	Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy. <i>Gynecologic Oncology</i> , 2021, 163, 371-377.	1.4	2
36	Biomarker Expression in Multifocal Vulvar High-Grade Squamous Intraepithelial Lesions. <i>Cancers</i> , 2021, 13, 5646.	3.7	1